const p=(e="")=>e==="pathogenesis"?i():e==="immunity"?t():e==="pathology"?n():e==="clinical-presentation"?a():e==="examination-findings"?o():e==="investigations"?r():e==="treatment"?s():e==="complications"?l():e==="prevention"?c():e==="kenya-context"?m():[{title:"Urinary Tract Infections in Pregnancy - Comprehensive Management",clickableItems:[{text:"ğŸ§¬ Pathogenesis of UTI in Pregnancy",sectionId:"pathogenesis"},{text:"ğŸ›¡ï¸ Maternal Immunity and UTI",sectionId:"immunity"},{text:"ğŸ”¬ Pathology and Microbiology",sectionId:"pathology"},{text:"ğŸ©º Clinical Presentation",sectionId:"clinical-presentation"},{text:"ğŸ‘©â€âš•ï¸ Examination Findings",sectionId:"examination-findings"},{text:"ğŸ” Investigations and Diagnosis",sectionId:"investigations"},{text:"ğŸ’Š Treatment Protocols",sectionId:"treatment"},{text:"âš ï¸ Maternal and Fetal Complications",sectionId:"complications"},{text:"ğŸ›¡ï¸ Prevention Strategies",sectionId:"prevention"},{text:"ğŸ‡°ğŸ‡ª Kenya-Specific Guidelines",sectionId:"kenya-context"}]},{title:"UTI in Pregnancy Overview",points:["ğŸ“Š **Prevalence**: Asymptomatic bacteruria 2-10%, Cystitis 1-3%, Pyelonephritis 1-2%","âš¡ **Risk Factors**: Pregnancy physiology, sexual activity, diabetes, previous UTI","ğŸ¦  **Common Pathogens**: E. coli (80-85%), Klebsiella, Enterococcus, Group B Strep","ğŸ¤° **Pregnancy Changes**: Urinary stasis, immune suppression, anatomical changes","âš ï¸ **Complications**: Preterm labor, low birth weight, maternal sepsis","ğŸ’Š **Treatment Goals**: Cure infection, prevent complications, avoid teratogenic drugs","ğŸ”„ **Screening**: Universal screening for asymptomatic bacteruria recommended"]},{title:"Classification and Management Summary",subsections:[{title:"Asymptomatic Bacteruria",points:["ğŸ”¬ **Definition**: â‰¥10âµ CFU/mL same organism, no symptoms","ğŸ“Š **Prevalence**: 2-10% of pregnant women","ğŸ’Š **Treatment**: 3-7 day antibiotic course mandatory","ğŸ¯ **Screening**: At first prenatal visit and each trimester"]},{title:"Acute Cystitis",points:["ğŸ’§ **Symptoms**: Dysuria, frequency, urgency, suprapubic pain","ğŸ”¬ **Diagnosis**: â‰¥10Â² CFU/mL with symptoms","ğŸ’Š **Treatment**: 3-7 day antibiotic course","âš¡ **Urgency**: Prompt treatment to prevent ascending infection"]},{title:"Acute Pyelonephritis",points:["ğŸ”¥ **Symptoms**: Fever, flank pain, nausea, vomiting","ğŸ¥ **Management**: Hospitalization usually required","ğŸ’‰ **Treatment**: IV antibiotics initially, 10-14 day course","âš ï¸ **Complications**: Sepsis, preterm labor, ARDS"]}]}],i=()=>[{title:"Pathogenesis of UTI in Pregnancy",subsections:[{title:"Anatomical Changes in Pregnancy",points:["ğŸ«˜ **Renal System**: Kidney length increases by 1-1.5cm","ğŸ’§ **Urinary System**: Glomerular filtration rate increases 40-50%","ğŸŒŠ **Collecting System**: Dilation of renal pelvis and ureters","âš¡ **Ureteral Changes**: Right-sided predominance due to dextrorotation","ğŸ”„ **Bladder Changes**: Decreased tone, increased capacity, incomplete emptying","ğŸ“ **Anatomical Compression**: Gravid uterus compresses ureters at pelvic brim"]},{title:"Physiological Changes Predisposing to UTI",points:["ğŸ’§ **Urinary Stasis**: Decreased ureteral peristalsis due to progesterone","ğŸŒŠ **Vesicoureteral Reflux**: Increased incidence in pregnancy","âš¡ **Bladder Dysfunction**: Incomplete emptying, increased residual volume","ğŸ”„ **Glycosuria**: Increased glucose in urine promotes bacterial growth","ğŸ’« **pH Changes**: Increased urinary pH favors bacterial multiplication","ğŸ§¬ **Immunological Changes**: Decreased neutrophil chemotaxis"]},{title:"Hormonal Influences",points:["ğŸŒ™ **Progesterone Effects**: Smooth muscle relaxation, decreased peristalsis","âš¡ **Estrogen Effects**: Increased vaginal glycogen, altered flora","ğŸ’« **Relaxin**: Further smooth muscle relaxation","ğŸ”„ **Aldosterone**: Increased sodium retention, fluid retention","ğŸ§¬ **Cortisol**: Mild immunosuppression","ğŸ’§ **ADH Changes**: Altered water handling"]},{title:"Bacterial Pathogenesis",points:["ğŸ¦  **Ascending Route**: Primary pathway from perineum to bladder","âš¡ **Bacterial Adherence**: Uropathogenic adhesins bind to uroepithelium","ğŸ”„ **Biofilm Formation**: Protects bacteria from host defenses","ğŸ’« **Virulence Factors**: Hemolysin, CNF1, aerobactin production","ğŸ§¬ **Immune Evasion**: Molecular mimicry, antigenic variation","ğŸŒŠ **Tissue Invasion**: Internalization into uroepithelial cells"]},{title:"Host-Pathogen Interactions",points:["ğŸ›¡ï¸ **Innate Immunity**: TLR4 recognition of bacterial LPS","âš¡ **Inflammatory Response**: Cytokine cascade activation","ğŸ’« **Complement Activation**: Alternative pathway predominance","ğŸ”„ **Neutrophil Function**: Altered in pregnancy","ğŸ§¬ **Antibody Response**: Variable effectiveness","ğŸŒŠ **Local Defenses**: Tamm-Horsfall protein, lactoferrin"]}]}],t=()=>[{title:"Maternal Immunity and UTI Susceptibility",subsections:[{title:"Innate Immune Changes in Pregnancy",points:["ğŸ›¡ï¸ **Neutrophil Function**: Decreased chemotaxis and bactericidal activity","âš¡ **Macrophage Activity**: Altered polarization toward M2 phenotype","ğŸ’« **Natural Killer Cells**: Reduced cytotoxic activity","ğŸ”„ **Complement System**: Mild consumption, decreased activity","ğŸŒŠ **Antimicrobial Peptides**: Variable expression of defensins","ğŸ§¬ **Toll-like Receptors**: Altered TLR expression and signaling"]},{title:"Adaptive Immune Modifications",points:["ğŸ¯ **T Helper Cells**: Shift from Th1 to Th2 predominance","âš¡ **Regulatory T Cells**: Increased numbers and activity","ğŸ’« **B Cell Function**: Altered antibody production patterns","ğŸ”„ **Cytokine Profile**: Decreased IL-2, IFN-Î³; increased IL-4, IL-10","ğŸ§¬ **HLA Expression**: Altered HLA-G expression","ğŸŒŠ **Memory Responses**: Blunted recall responses"]},{title:"Local Urogenital Immunity",points:["ğŸ’§ **Secretory IgA**: Decreased local antibody production","âš¡ **Lactoferrin**: Reduced antimicrobial protein levels","ğŸ’« **Lysozyme**: Decreased enzyme activity","ğŸ”„ **Mucin Production**: Altered glycoprotein barrier function","ğŸŒŠ **Microbiome Changes**: Altered vaginal and urethral flora","ğŸ§¬ **Cytokine Network**: Local immunosuppression"]},{title:"Hormonal Immune Modulation",points:["ğŸŒ™ **Progesterone**: Immunosuppressive effects on lymphocytes","âš¡ **Estrogen**: Biphasic effects on immune function","ğŸ’« **Cortisol**: Stress hormone immunosuppression","ğŸ”„ **HCG**: Immune modulatory effects","ğŸ§¬ **Prolactin**: Influences on immune cell function","ğŸŒŠ **Relaxin**: Effects on tissue barriers"]},{title:"Maternal-Fetal Immune Interface",points:["ğŸ¤° **Immune Tolerance**: Systemic tolerance to prevent fetal rejection","âš¡ **Regulatory Networks**: Complex cytokine regulation","ğŸ’« **Cellular Interactions**: Altered immune cell trafficking","ğŸ”„ **Antibody Transfer**: Maternal IgG transfer to fetus","ğŸ§¬ **Immune Memory**: Impact on long-term immune responses","ğŸŒŠ **Inflammation Control**: Anti-inflammatory bias"]}]}],n=()=>[{title:"Pathology and Microbiology of UTI in Pregnancy",subsections:[{title:"Common Bacterial Pathogens",points:["ğŸ¦  **Escherichia coli**: 75-85% of cases, uropathogenic strains","âš¡ **Klebsiella pneumoniae**: 5-10%, often antibiotic resistant","ğŸ’« **Enterococcus faecalis**: 5-10%, intrinsic ampicillin resistance","ğŸ”„ **Staphylococcus saprophyticus**: 2-5%, honeymoon cystitis","ğŸŒŠ **Group B Streptococcus**: 2-5%, neonatal transmission risk","ğŸ§¬ **Proteus mirabilis**: 1-3%, alkaline urine, struvite stones"]},{title:"Antibiotic Resistance Patterns",points:["ğŸ’Š **Ampicillin**: High resistance rates (30-50%)","âš¡ **Trimethoprim-Sulfamethoxazole**: Increasing resistance (15-25%)","ğŸ’« **Fluoroquinolones**: Avoided in pregnancy, resistance emerging","ğŸ”„ **Extended-Spectrum Beta-Lactamases**: Increasing concern","ğŸŒŠ **Vancomycin-Resistant Enterococci**: Rare but serious","ğŸ§¬ **Carbapenem Resistance**: Emerging threat"]},{title:"Histopathological Changes",points:["ğŸ”¬ **Acute Inflammation**: Neutrophil infiltration in tissues","âš¡ **Chronic Changes**: Lymphocytic infiltration, fibrosis","ğŸ’« **Tubular Damage**: Epithelial cell necrosis, cast formation","ğŸ”„ **Interstitial Nephritis**: Progressive inflammatory changes","ğŸŒŠ **Glomerular Changes**: Usually minimal in uncomplicated UTI","ğŸ§¬ **Scarring**: Long-term sequelae of recurrent infections"]},{title:"Diagnostic Microbiology",points:["ğŸ§ª **Colony Count**: â‰¥10âµ CFU/mL for asymptomatic bacteruria","âš¡ **Symptomatic UTI**: â‰¥10Â² CFU/mL with symptoms","ğŸ’« **Mixed Flora**: Usually indicates contamination","ğŸ”„ **Pyuria**: >10 WBC/hpf, indicator of inflammation","ğŸŒŠ **Nitrite Test**: Positive with nitrate-reducing bacteria","ğŸ§¬ **Leukocyte Esterase**: Enzyme from neutrophils"]},{title:"Special Considerations",points:["ğŸ¤° **Group B Strep**: Colonization vs infection distinction","âš¡ **Candida**: Increased risk in pregnancy, usually asymptomatic","ğŸ’« **Tuberculosis**: Rare but important in endemic areas","ğŸ”„ **Viral Infections**: HSV, CMV in immunocompromised","ğŸŒŠ **Parasitic**: Schistosomiasis in endemic regions","ğŸ§¬ **Polymicrobial**: Multiple organisms in complicated cases"]}]}],a=()=>[{title:"Clinical Presentation of UTI in Pregnancy",subsections:[{title:"Asymptomatic Bacteruria",points:["ğŸ¤ **Definition**: No urinary symptoms despite significant bacteruria","ğŸ“Š **Prevalence**: 2-10% of pregnant women","âš¡ **Detection**: Only through routine screening","ğŸ”„ **Progression Risk**: 25-40% develop symptomatic UTI if untreated","ğŸ¯ **Complications**: Preterm labor, low birth weight","ğŸ’Š **Treatment Necessity**: Always treat in pregnancy"]},{title:"Acute Cystitis Presentation",points:["ğŸ’§ **Dysuria**: Burning sensation during urination","âš¡ **Frequency**: Increased urination frequency","ğŸš¶â€â™€ï¸ **Urgency**: Sudden, strong urge to urinate","ğŸ’” **Suprapubic Pain**: Lower abdominal discomfort","ğŸ©¸ **Hematuria**: Blood in urine (gross or microscopic)","ğŸŒ™ **Nocturia**: Nighttime urination frequency"]},{title:"Acute Pyelonephritis Presentation",points:["ğŸ”¥ **Fever**: >38Â°C, often with chills and rigors","ğŸ’” **Flank Pain**: Unilateral or bilateral costovertebral angle pain","ğŸ¤¢ **Nausea and Vomiting**: Gastrointestinal symptoms","ğŸ˜´ **Malaise**: General feeling of unwellness","ğŸ¤• **Headache**: Associated systemic symptoms","âš¡ **Lower UTI Symptoms**: May or may not be present"]},{title:"Systemic Manifestations",points:["ğŸŒ¡ï¸ **Temperature**: Fever pattern and response to treatment","ğŸ’“ **Cardiovascular**: Tachycardia, hypotension in severe cases","ğŸ« **Respiratory**: Tachypnea, dyspnea if ARDS develops","ğŸ§  **Neurological**: Confusion, altered mental status","ğŸ¤° **Obstetric**: Uterine contractions, preterm labor signs","ğŸ’§ **Fluid Balance**: Dehydration, decreased urine output"]},{title:"Pregnancy-Specific Considerations",points:["âš¡ **Preterm Labor**: Uterine contractions may be first sign","ğŸ¤° **Fetal Effects**: Reduced fetal movements, growth concerns","ğŸ”„ **Symptom Masking**: Normal pregnancy symptoms may obscure UTI","ğŸ’« **Positional Changes**: Symptoms may vary with position","ğŸŒŠ **Gestational Age**: Presentation may vary by trimester","ğŸ¯ **Risk Stratification**: High-risk pregnancy considerations"]}]}],o=()=>[{title:"Examination Findings in UTI During Pregnancy",subsections:[{title:"General Examination",points:["ğŸŒ¡ï¸ **Vital Signs**: Temperature, pulse, blood pressure, respiratory rate","ğŸ˜Ÿ **General Appearance**: Toxic vs well-appearing, hydration status","ğŸ’§ **Hydration**: Skin turgor, mucous membranes, capillary refill","ğŸ‘ï¸ **Eyes**: Conjunctival pallor, scleral icterus","ğŸ’“ **Cardiovascular**: Heart rate, rhythm, murmurs","ğŸ« **Respiratory**: Breathing pattern, lung sounds"]},{title:"Abdominal Examination",points:["ğŸ‘ï¸ **Inspection**: Gravid uterus, surgical scars, distension","ğŸ¤² **Palpation**: Fundal height, fetal presentation, uterine tenderness","ğŸ’” **Suprapubic Tenderness**: Bladder distension, cystitis","âš¡ **Rebound Tenderness**: May indicate peritoneal irritation","ğŸµ **Percussion**: Bladder dullness, shifting dullness","ğŸ‘‚ **Auscultation**: Fetal heart rate, uterine activity"]},{title:"Costovertebral Angle Assessment",points:["ğŸ‘Š **CVA Tenderness**: Percussion tenderness, Murphy's punch sign","ğŸ’” **Pain Characterization**: Sharp, dull, radiating patterns","âš¡ **Bilateral Assessment**: Compare both sides","ğŸ”„ **Positional Changes**: Pain with movement, position","ğŸ’« **Associated Findings**: Muscle spasm, guarding","ğŸ¯ **Severity Assessment**: Pain scale documentation"]},{title:"Obstetric Examination",points:["ğŸ“ **Fundal Height**: Appropriate for gestational age","ğŸ‘¶ **Fetal Assessment**: Heart rate, movements, presentation","âš¡ **Uterine Activity**: Contractions, irritability, tenderness","ğŸ’§ **Membrane Status**: Intact membranes, signs of rupture","ğŸ”„ **Cervical Assessment**: If indicated by symptoms","ğŸ¯ **Fetal Well-being**: CTG monitoring if appropriate"]},{title:"Genitourinary Examination",points:["ğŸ‘ï¸ **External Genitalia**: Erythema, discharge, lesions","ğŸ’§ **Urethral Meatus**: Inflammation, discharge","ğŸ” **Vaginal Examination**: If clinically indicated","âš¡ **Bladder Palpation**: Distension, tenderness","ğŸ’« **Pelvic Assessment**: Adnexal masses, cervical motion tenderness","ğŸŒŠ **Discharge Characteristics**: Color, odor, consistency"]},{title:"Systemic Assessment",points:["ğŸ§  **Neurological**: Mental status, orientation, reflexes","ğŸ’“ **Circulatory**: Peripheral perfusion, edema","ğŸ« **Pulmonary**: Respiratory distress, crackles","ğŸ”¥ **Inflammatory**: Lymphadenopathy, skin changes","ğŸ‘ï¸ **Ophthalmologic**: Papilledema, retinal changes","ğŸ¦´ **Musculoskeletal**: Joint examination if systemic symptoms"]}]}],r=()=>[{title:"Investigations for UTI in Pregnancy",subsections:[{title:"Urine Analysis and Microscopy",points:["ğŸ”¬ **Dipstick Test**: Nitrites, leukocyte esterase, protein, glucose","ğŸ’§ **Microscopy**: WBC >10/hpf, RBC, bacteria, casts","âš¡ **Pyuria**: Significant if >10 WBC/hpf","ğŸ©¸ **Hematuria**: May indicate complicated UTI","ğŸ§‚ **Specific Gravity**: Concentration assessment","ğŸ”„ **pH**: Normal 4.6-8.0, alkaline suggests certain organisms"]},{title:"Urine Culture and Sensitivity",points:["ğŸ§ª **Collection Method**: Clean-catch midstream, catheter if necessary","ğŸ“Š **Colony Count**: â‰¥10âµ CFU/mL asymptomatic, â‰¥10Â² symptomatic","ğŸ¦  **Organism Identification**: Species-specific identification","ğŸ’Š **Antibiotic Sensitivity**: Pregnancy-safe antibiotic testing","â° **Timing**: Results available 24-48 hours","ğŸ”„ **Repeat Testing**: Test of cure 1-2 weeks post-treatment"]},{title:"Blood Investigations",points:["ğŸ©¸ **Complete Blood Count**: WBC, neutrophilia, anemia","âš¡ **Blood Cultures**: If fever >38Â°C or systemic symptoms","ğŸ§ª **Inflammatory Markers**: CRP, ESR elevation","ğŸ’§ **Renal Function**: Creatinine, BUN, electrolytes","ğŸ¯ **Blood Glucose**: Exclude diabetes mellitus","ğŸ”„ **Liver Function**: If systemic involvement suspected"]},{title:"Imaging Studies",points:["ğŸ“± **Renal Ultrasound**: First-line imaging, assess hydronephrosis","ğŸ” **Bladder Ultrasound**: Post-void residual, bladder abnormalities","âš¡ **Doppler Studies**: Renal blood flow assessment","ğŸ’« **MRI**: If complications suspected, avoid gadolinium","ğŸš« **CT Scan**: Avoid due to radiation, only if life-threatening","ğŸ¯ **IVP**: Generally contraindicated in pregnancy"]},{title:"Specialized Tests",points:["ğŸ¦  **Group B Strep**: Rectovaginal swab at 35-37 weeks","ğŸ’§ **24-hour Urine**: Protein, creatinine clearance if indicated","ğŸ§¬ **PCR Testing**: For specific pathogens if clinical suspicion","âš¡ **Fungal Culture**: If yeast seen on microscopy","ğŸ”¬ **AFB Stain**: If TB suspected in endemic areas","ğŸ¯ **Viral Studies**: HSV, CMV if immunocompromised"]},{title:"Monitoring Parameters",points:["ğŸŒ¡ï¸ **Temperature Monitoring**: Fever curve, response to treatment","ğŸ’§ **Fluid Balance**: Input/output, weight monitoring","âš¡ **Vital Signs**: Regular monitoring especially if hospitalized","ğŸ¤° **Fetal Monitoring**: CTG if gestational age appropriate","ğŸ“Š **Laboratory Trends**: Serial blood counts, inflammatory markers","ğŸ”„ **Clinical Response**: Symptom improvement timeline"]}]}],s=()=>[{title:"Treatment of UTI in Pregnancy",subsections:[{title:"Asymptomatic Bacteruria Treatment",points:["ğŸ’Š **First-Line**: Nitrofurantoin 100mg BID x 5-7 days","âš¡ **Alternative**: Amoxicillin 500mg TID x 3-7 days (if sensitive)","ğŸ§ª **Culture-Guided**: Adjust based on sensitivity results","ğŸ”„ **Follow-up**: Test of cure 1-2 weeks post-treatment","ğŸ“Š **Monitoring**: Monthly urine cultures thereafter","ğŸ¯ **Treatment Goal**: Prevent progression to symptomatic UTI"]},{title:"Acute Cystitis Treatment",points:["ğŸ’Š **First-Line**: Nitrofurantoin 100mg BID x 5-7 days","âš¡ **Second-Line**: Amoxicillin-clavulanate 875/125mg BID x 5-7 days","ğŸ§¬ **Third-Line**: Cephalexin 500mg QID x 7 days","ğŸ”„ **Symptom Relief**: Phenazopyridine 200mg TID x 2 days (if available)","ğŸ’§ **Supportive Care**: Increased fluid intake, frequent voiding","ğŸ“Š **Follow-up**: Clinical improvement expected 48-72 hours"]},{title:"Acute Pyelonephritis Treatment",points:["ğŸ¥ **Hospitalization**: Usually required for IV antibiotics","ğŸ’‰ **Initial IV Therapy**: Ceftriaxone 1-2g daily OR Ampicillin 2g q6h + Gentamicin","âš¡ **Oral Transition**: When fever-free x 24-48 hours","ğŸ”„ **Total Duration**: 10-14 days total therapy","ğŸ’§ **Supportive Care**: IV fluids, antipyretics, antiemetics","ğŸ“Š **Monitoring**: Daily clinical assessment, vital signs"]},{title:"Pregnancy-Safe Antibiotics",points:["âœ… **Safe Options**: Nitrofurantoin (avoid at term), Amoxicillin, Cephalexin","âš¡ **Conditionally Safe**: Amoxicillin-clavulanate, Azithromycin","âš ï¸ **Use with Caution**: Gentamicin (monitor levels), Vancomycin","ğŸš« **Contraindicated**: Fluoroquinolones, Tetracyclines, Trimethoprim (1st trimester)","ğŸ§¬ **FDA Categories**: Prefer Category A and B drugs","ğŸ”„ **Special Considerations**: Renal function, gestational age"]},{title:"Resistant Organism Management",points:["ğŸ§ª **ESBL Producers**: Carbapenem therapy (Meropenem)","âš¡ **VRE**: Linezolid or Daptomycin (limited pregnancy data)","ğŸ’« **MRSA**: Vancomycin with level monitoring","ğŸ”„ **Multiple Resistance**: Infectious disease consultation","ğŸ¯ **De-escalation**: Narrow spectrum once sensitivities known","ğŸ“Š **Monitoring**: Close clinical and laboratory monitoring"]},{title:"Supportive Management",points:["ğŸ’§ **Hydration**: Adequate oral or IV fluid intake","ğŸŒ¡ï¸ **Fever Management**: Acetaminophen 650mg q6h PRN","ğŸ¤¢ **Nausea Control**: Ondansetron 4-8mg q8h PRN","âš¡ **Pain Relief**: Acetaminophen, avoid NSAIDs","ğŸ”„ **Bladder Care**: Frequent voiding, complete emptying","ğŸ¤° **Obstetric Monitoring**: Fetal surveillance, preterm labor watch"]}]}],l=()=>[{title:"Complications of UTI in Pregnancy",subsections:[{title:"Maternal Complications - Immediate",points:["ğŸ”¥ **Sepsis**: Life-threatening systemic infection","ğŸ’” **Septic Shock**: Hypotension, organ dysfunction","ğŸ« **ARDS**: Acute respiratory distress syndrome","ğŸ’§ **Acute Renal Failure**: Prerenal or intrinsic renal injury","âš¡ **DIC**: Disseminated intravascular coagulation","ğŸ§  **Encephalopathy**: Altered mental status, seizures"]},{title:"Maternal Complications - Long-term",points:["ğŸ”„ **Recurrent UTI**: 20-30% recurrence rate","ğŸ’” **Chronic Pyelonephritis**: Progressive renal scarring","âš¡ **Hypertension**: Chronic kidney disease sequelae","ğŸ§¬ **Chronic Kidney Disease**: Long-term renal impairment","ğŸ’§ **Chronic Pain**: Persistent flank or pelvic pain","ğŸ”„ **Antibiotic Resistance**: From repeated infections"]},{title:"Obstetric Complications",points:["âš¡ **Preterm Labor**: Increased risk 2-3 fold","ğŸ¤° **Preterm Birth**: Delivery <37 weeks gestation","ğŸ’” **PROM/PPROM**: Premature rupture of membranes","ğŸ§  **Chorioamnionitis**: Intraamniotic infection","ğŸ¤• **Maternal Fever**: Intrapartum hyperthermia","ğŸ¥ **Cesarean Delivery**: Increased operative delivery rates"]},{title:"Fetal and Neonatal Complications",points:["âš–ï¸ **Low Birth Weight**: <2500g at term","ğŸ§  **Intrauterine Growth Restriction**: Fetal growth below 10th percentile","âš¡ **Fetal Distress**: Abnormal fetal heart rate patterns","ğŸ’” **Stillbirth**: Increased risk with severe maternal infection","ğŸ¤’ **Neonatal Sepsis**: Early-onset bacterial infection","ğŸ« **Respiratory Distress**: Prematurity-related complications"]},{title:"Specific Pathogen Complications",points:["ğŸ¦  **Group B Strep**: Neonatal sepsis, meningitis risk","âš¡ **E. coli**: Neonatal sepsis, most common cause","ğŸ’« **Klebsiella**: Antibiotic-resistant infections","ğŸ”„ **Enterococcus**: VRE transmission risk","ğŸ§¬ **Listeria**: Intrauterine infection, fetal loss","ğŸŒŠ **Candida**: Congenital candidiasis (rare)"]},{title:"Treatment-Related Complications",points:["ğŸ’Š **Antibiotic Side Effects**: Diarrhea, rash, allergic reactions","ğŸ§¬ **C. difficile Colitis**: Antibiotic-associated diarrhea","âš¡ **Drug Resistance**: Selection of resistant organisms","ğŸ’« **Nephrotoxicity**: Aminoglycoside-induced kidney damage","ğŸ”„ **Ototoxicity**: Eighth cranial nerve damage","ğŸ¤° **Teratogenicity**: Fetal effects from inappropriate antibiotics"]}]}],c=()=>[{title:"Prevention of UTI in Pregnancy",subsections:[{title:"Primary Prevention Strategies",points:["ğŸ’§ **Adequate Hydration**: 8-10 glasses water daily","ğŸš½ **Proper Hygiene**: Front-to-back wiping, regular bathing","âš¡ **Complete Bladder Emptying**: Avoid holding urine, double voiding","ğŸ› **Voiding Habits**: Urinate before and after intercourse","ğŸ‘™ **Clothing Choices**: Cotton underwear, avoid tight clothing","ğŸ§¼ **Genital Hygiene**: Mild soap, avoid harsh chemicals"]},{title:"Behavioral Modifications",points:["ğŸš½ **Frequent Voiding**: Every 2-3 hours during day","ğŸ’§ **Post-coital Voiding**: Within 15 minutes of intercourse","ğŸ› **Shower vs Bath**: Prefer showers to reduce bacteria","ğŸ§» **Hygiene Products**: Avoid perfumed products, douches","ğŸ‘— **Loose Clothing**: Reduce moisture retention","ğŸ **Cranberry Products**: May reduce adherence (limited evidence)"]},{title:"Medical Prevention",points:["ğŸ” **Screening Programs**: Universal screening for asymptomatic bacteruria","ğŸ’Š **Prophylactic Antibiotics**: For recurrent UTI (>2 episodes)","ğŸ§ª **Regular Monitoring**: Monthly urine cultures after treatment","âš¡ **Early Treatment**: Prompt treatment of asymptomatic bacteruria","ğŸ¯ **Risk Assessment**: Identify high-risk patients","ğŸ“Š **Follow-up Care**: Structured follow-up protocols"]},{title:"Prophylactic Antibiotic Regimens",points:["ğŸ’Š **Nitrofurantoin**: 50-100mg daily at bedtime","âš¡ **Cephalexin**: 250mg daily or twice daily","ğŸ§¬ **Duration**: Throughout pregnancy after second UTI","ğŸ”„ **Monitoring**: Monthly urine cultures on prophylaxis","ğŸ“Š **Resistance Surveillance**: Monitor for breakthrough infections","ğŸ¯ **Discontinuation**: Consider stopping if no breakthrough"]},{title:"High-Risk Patient Management",points:["ğŸ” **Enhanced Screening**: More frequent urine cultures","ğŸ’Š **Early Intervention**: Lower threshold for treatment","ğŸ¥ **Specialist Referral**: Nephrology, maternal-fetal medicine","ğŸ“Š **Close Monitoring**: Regular clinical assessments","âš¡ **Delivery Planning**: Timing and mode of delivery considerations","ğŸ¤° **Postpartum Care**: Continued monitoring postpartum"]},{title:"Patient Education Components",points:["ğŸ“š **Disease Awareness**: Understanding UTI risks in pregnancy","âš¡ **Symptom Recognition**: When to seek medical care","ğŸ’Š **Medication Compliance**: Importance of completing antibiotics","ğŸ”„ **Follow-up Importance**: Need for test of cure","ğŸ¯ **Prevention Strategies**: Lifestyle modifications","ğŸš¨ **Warning Signs**: When to seek emergency care"]}]}],m=()=>[{title:"Kenya-Specific Considerations for UTI in Pregnancy",subsections:[{title:"Epidemiology in Kenya",points:["ğŸ“Š **Prevalence**: Asymptomatic bacteruria 6-12%, higher than global average","ğŸ¥ **Healthcare Access**: Limited laboratory facilities in rural areas","ğŸ’° **Economic Impact**: Cost of antibiotics relative to income","ğŸ“ **Health Literacy**: Variable understanding of UTI prevention","â° **Presentation Delays**: Late presentation due to distance, cost","ğŸŒ **Regional Variations**: Urban vs rural prevalence differences"]},{title:"Common Pathogens in Kenya",points:["ğŸ¦  **E. coli**: Remains most common (70-80%)","âš¡ **Klebsiella**: Higher prevalence (10-15%)","ğŸ’« **Enterococcus**: Significant cause (8-12%)","ğŸ”„ **S. saprophyticus**: Common in young women","ğŸŒŠ **Candida**: Higher prevalence due to climate","ğŸ§¬ **TB**: Consider in chronic, resistant cases"]},{title:"Antibiotic Resistance Patterns",points:["ğŸ’Š **Ampicillin**: Very high resistance (60-80%)","âš¡ **Cotrimoxazole**: High resistance (40-60%)","ğŸ’« **Nitrofurantoin**: Good sensitivity (80-90%)","ğŸ”„ **Cephalosporins**: Generally effective","ğŸŒŠ **Gentamicin**: Effective but needs monitoring","ğŸ§¬ **ESBL**: Increasing concern in urban areas"]},{title:"Healthcare System Challenges",points:["ğŸ¥ **Laboratory Capacity**: Limited culture facilities","ğŸ” **Diagnostic Delays**: Results may take days","ğŸ’° **Cost Barriers**: Out-of-pocket expenses for investigations","ğŸš— **Geographic Access**: Distance to healthcare facilities","ğŸ‘¨â€âš•ï¸ **Staffing**: Limited specialized personnel","ğŸ“š **Training Needs**: Ongoing education requirements"]},{title:"Adapted Management Strategies",points:["ğŸ’Š **Empirical Treatment**: Based on local resistance patterns","ğŸ§ª **Selective Culture**: Prioritize high-risk cases","ğŸ“± **Point-of-Care Testing**: Dipstick and microscopy","âš¡ **Simplified Protocols**: Clear, actionable guidelines","ğŸ¯ **Risk Stratification**: Focus resources on high-risk patients","ğŸ“Š **Surveillance**: Local antibiogram development"]},{title:"Resource Optimization",points:["ğŸ’Š **Essential Medicines**: Ensure availability of first-line antibiotics","ğŸ” **Point-of-Care Diagnostics**: Rapid testing methods","ğŸ‘¨â€âš•ï¸ **Task Shifting**: Train non-physician providers","ğŸ’° **Cost-Effective Protocols**: Generic medications, simplified regimens","ğŸ¥ **Integrated Services**: Combine with routine antenatal care","ğŸ“š **Community Education**: Prevention-focused programs"]},{title:"Quality Improvement Initiatives",points:["ğŸ“Š **Data Collection**: Standardized reporting systems","ğŸ¯ **Performance Indicators**: Treatment success rates, complications","ğŸ”„ **Continuous Monitoring**: Regular review of outcomes","ğŸ‘¥ **Multidisciplinary Teams**: Collaborative care models","ğŸ“š **Continuing Education**: Regular training updates","ğŸŒ **Best Practice Sharing**: Inter-facility learning networks"]}]}];export{p as getUTIPregnancyContent};
